EUCTR2006-004772-12-DK进行中（未招募）1 期
Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide.
ordic Lymphoma Group0 个研究点目标入组 70 人开始时间: 2006年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria
- •Pathologically verified primary central nervous system lymphoma
- •No prior PCNSL treatment. Patients treated with steroids alone are eligible
- •No signs of lymhpoma outside the CNS
- •ECOG performance status 0-4 (Appendix 1)
- •Age > 18 and < 75 years
- •Written informed consent from the patient or guardian
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria
- •Cardiac failure > 3 (NYHA , Appendix 2)
- •Pregnancy or lactation
- •Previous malignancy unless diseasefree for at least five years
- •Active infection
- •Positive HIV status
- •Organ transplantation
- •Serious psychiatric illness
- •Prior radiotherapy to the brain
- •5.2.9 Concomitant anti-inflammatory medication that cannot be discontinued
- •5.2.10 Creatinine clearance < 60 ml/minute calculated by Cockcroft and Gault formula
- •(Appendix 4)
- •5.2.11 Peripheral blood count with granulocytes <1.5 x 109L or platelets < 100 x 109L
- •5.2.12 Serum bilirubin >1.5 times or ASAT and alkaline phosphatase >2 times upper limits
- •5.2.13Known anaphylaxis or IgE-mediated hypersensitivity to murine protein or any
- •component of Rituximab excludes patients from Rituximab treatment, but not from
- •the remaining part of the study
研究者
相似试验
进行中（未招募）
不适用
Immunochemotherapy in primary central nervous system lymphoma with rituximab, HD-MTX, HD Ara-C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide,and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide - NLG PCNSEUCTR2006-004772-12-FIordic lymphoma group70
进行中（未招募）
不适用
Immunochemotherapy in primary central nervous system lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide.ewly diagnosed Primary Central Nervous LymphomaEUCTR2006-004772-12-SEordic Lymphoma Group70
已完成
2 期
Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) LymphomaCentral Nervous System LymphomaNCT01458730University of Aarhus66
招募中
2 期
Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma2024-519046-79-00Oulu University Hospital100
已完成
不适用
Treatment for CD20-positive central nervus system lymphoma with autologous serum and rituximab into the ventricleCD20-positive primary central nervus system lymphoma, or relapsed CD20-positive non-Hodgkin lymphoma in CNS aloneJPRN-UMIN000000968Division of Hematology, University of Tsukuba5